We are pleased to announce the addition of the dual peroxisome proliferator-activated receptor (PPAR)α/δ agonist elafibranor (Iqirvo®) to the hepatology drug interaction checker. Elafibranor is indicated for primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid, in adults with an inadequate response to ursodeoxycholic acid alone, or as a monotherapy in adults who cannot tolerate ursodeoxycholic acid.
All our Interaction Summary Tables have been updated to include elafibranor, and a downloadable update is available for our mobile apps.
Find the PK Factsheet for elafibranor here.
